<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04887961</url>
  </required_header>
  <id_info>
    <org_study_id>MITO36</org_study_id>
    <nct_id>NCT04887961</nct_id>
  </id_info>
  <brief_title>Reprab Study: PLD + Trabectedin Rechallenge</brief_title>
  <acronym>MITO36</acronym>
  <official_title>Rechallenge With PLD Added to Trabectedine in Recurrent Ovarian Cancer: a Multicenter Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN&#xD;
      CANCER: A MULTICENTER, PROSPECTIVE TRIAL&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate that rechallenge with pegylated liposomal doxorubicin (PLD) with the&#xD;
      combination of trabectedin (Yondelis®) is active (objective response rate) in relapsed&#xD;
      ovarian cancer patients who have already received pegylated liposomal doxorubicin and&#xD;
      progress within 6-12 months after the end of last platinum or in fully platinum sensitive&#xD;
      patients not able to receive or not willing to receive other platinum treatments&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective multicenter phase II study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>30 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Relapsed Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLD 30 mg/mq 1 h iv + Trabectedin 1.1 mg/mq 3 h iv d1q21 up to 6 cycles or PD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLD and Trabectedin rechallenge</intervention_name>
    <description>Platinum partially sensitive patients i.e. patients who recur with a platinum free interval between 6 and 12 months, who have previously received pegylated liposomal doxorubicin and are suitable for rechallenge with pegylated liposomal doxorubicin (PLD) with the combination of trabectedin (Yondelis®) and relapsed ovarian cancer fully platinum sensitive patients not able to receive or not willing to receive other platinum treatments</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Female aged ≥ 18 years.&#xD;
&#xD;
          -  Histologically or cytologically documented invasive epithelial ovarian cancer, primary&#xD;
             peritoneal carcinoma, or fallopian tube cancer&#xD;
&#xD;
          -  Platinum partially sensitive patients or fully platinum sensitive patients not able to&#xD;
             receive or not willing to receive other platinum treatments, who have previously&#xD;
             received pegylated liposomal doxorubicin (carboplatin- pegylated liposomal doxorubicin&#xD;
             or pegylated liposomal doxorubicin alone).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0- 1.&#xD;
&#xD;
          -  Subject has radiographically-documented measurable disease, as per RECIST 1.1 at study&#xD;
             entry (CA-125 rise not supported by radiological evidence of disease is not accepted&#xD;
             as criteria for defining progression).&#xD;
&#xD;
          -  Be able to receive IV dexamethasone or an equivalent IV corticosteroid.&#xD;
&#xD;
          -  Have all of the following:&#xD;
&#xD;
        hemoglobin ≥9 g/dL (without transfusion in the prior 7 days). Subjects may be enrolled into&#xD;
        the study while receiving recombinant erythropoietin provide they have received recombinant&#xD;
        erythropoietin for at least 4 weeks. before the first dose of study drug.&#xD;
&#xD;
        albumin &gt;25 g/L absolute neutrophil count (ANC) &gt;1,500/μL platelet count &gt;100,000/μL&#xD;
        (without transfusion in the prior 7 days) either a serum creatinine &lt;=1.5 mg/dL or a&#xD;
        calculated glomerular filtration rate &gt;60 mL/min/1.73 m2 (Cockcroft-Gault) CPK &lt;2.5 x upper&#xD;
        limit of normal (ULN) Have total bilirubin &lt;xULN. If total bilirubin is &gt; 1,5xULN, measure&#xD;
        direct and indirect bilirubin to evaluate for Gilbert's syndrome (if direct bilirubin is&#xD;
        within normal range, subject may be eligible).&#xD;
&#xD;
        Have alkaline phosphatase (ALP) 2.5xULN; if the ALP is &gt;2.5xULN, then an ALP liver fraction&#xD;
        or 5' nucleotidase must be &lt;ULN (as reported in absolute units of measure).&#xD;
&#xD;
        Have AST and ALT 2.5xULN. Have LVEF by MUGA scan or 2D-ECHO within normal limits for the&#xD;
        institution.&#xD;
&#xD;
          -  Patients must be in postmenopausal (at least 12 months consecutive amenorrhea, in the&#xD;
             appropriate age group and without other known or suspected cause), or have been&#xD;
             sterilized surgically&#xD;
&#xD;
          -  Adequate recovery from acute toxicity of any prior treatment&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Non-epithelial ovarian or mixed epithelial/non epithelial tumors (e.g., Mullerian&#xD;
             tumors)&#xD;
&#xD;
          -  Patients who did not respond to last platinum-based therapy or in whom last relapse&#xD;
             occurred &lt; 6 months from the last dose of platinum&#xD;
&#xD;
          -  Bowel obstruction, sub-occlusive disease or the presence of symptomatic brain&#xD;
             metastases&#xD;
&#xD;
          -  Known hypersensitivity to any of the components of pegylated liposomal doxorubicin or&#xD;
             TRABECTEDIN i.v. formulation&#xD;
&#xD;
          -  Previous treatment with Trabectedin&#xD;
&#xD;
          -  Known hypersensitivity to dexamethasone&#xD;
&#xD;
          -  Less than 4 weeks from last dose of therapy with any investigational agent, or&#xD;
             chemotherapy.&#xD;
&#xD;
          -  History of another neoplastic disease (except basal cell carcinoma or cervical&#xD;
             carcinoma in situ adequately treated) unless in remission for 3 years or longer&#xD;
&#xD;
          -  Myocardial failure within six months before enrolment, New York&#xD;
&#xD;
          -  Association (NYHA) Class II or worse heart failure, uncontrolled angina, severe&#xD;
             uncontrolled ventricular arythmias, clinically significant pericardial disease, or&#xD;
             electrocardiographic evidence of acute ischemic or active conduction system&#xD;
             abnormalities&#xD;
&#xD;
          -  Known significant chronic liver disease, such as cirrhosis or active hepatitis&#xD;
             (potential subjects who test positive for hepatitis B surface antigen or hepatitis C&#xD;
             antibodies are allowed provided they do not have active disease requiring antiviral&#xD;
             therapy). Also known history of liver carcinoma and cholangitis with abnormal liver&#xD;
             functionality&#xD;
&#xD;
          -  Concurrent severe medical problems or any unstable medical condition unrelated to&#xD;
             malignancy, which would significantly limit full compliance with the study or expose&#xD;
             the patient to extreme risk or decreased life expectancy&#xD;
&#xD;
          -  Known clinically relevant CNS metastases&#xD;
&#xD;
          -  Psychiatric disorder that prevents compliance with protocol&#xD;
&#xD;
          -  Patients with concurrent serious or uncontrolled infection&#xD;
&#xD;
          -  Patients in need of yellow fever vaccine while on study chemotherapy&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Breastfeeding women&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Any other unstable medical condition&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Giovanni Scambia, PI</last_name>
    <phone>0630153250</phone>
    <email>Giovanni.scambia@policlinicogemelli.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione Policlinico Gemelli IRCCS</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Marchetti, Dr</last_name>
      <phone>+390630151</phone>
      <email>claudia.marchetti@policlinicogemelli.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</investigator_affiliation>
    <investigator_full_name>SCAMBIA GIOVANNI</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>PLD</keyword>
  <keyword>Trabectedine</keyword>
  <keyword>Relapred ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

